Novartis therapy for infant muscle-wasting disease — potentially carrying a record $2 million price tag — is about to hit market

  • 📰 MarketWatch
  • ⏱ Reading Time:
  • 1 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 4%
  • Publisher: 97%

Indonesia Berita Berita

Indonesia Berita Terbaru,Indonesia Berita utama

A new treatment for an infant muscle-wasting disease is about to go on sale at a potential cost of $2 million, a record price tag likely to fuel the continuing scrutiny of how companies price their drugs and how insurers pay for them.

Berita ini telah kami rangkum agar Anda dapat membacanya dengan cepat. Jika Anda tertarik dengan beritanya, Anda dapat membaca teks lengkapnya di sini. Baca lebih lajut:

 /  🏆 3. in İD
 

Terima kasih atas komentar Anda. Komentar Anda akan dipublikasikan setelah ditinjau.

Permanent fixes = overpriced. Temporary relief with side effects = underpriced. Dont blame big Pharma. Dont blame insurance companies. Blame every person who pays these companies & says 'that's just how it is.' Everyone is free to make their own choices, except those babies.

Indonesia Berita Terbaru, Indonesia Berita utama

Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.

A $2 Million Drug Is About to Hit the MarketA new treatment for an infant muscle-wasting disease is about to go on sale at a potential cost of $2 million, a record price tag likely to fuel the continuing scrutiny of how companies price drugs and how insurers pay for it. This should be classified as a human rights violation. I'll take two, please. I don't believe $2 Million is justified. It is Medical Extortion, nothing more!
Sumber: WSJ - 🏆 98. / 63 Baca lebih lajut »